Research

Active surveillance nearly tripled in men with low-risk prostate disease

Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative "active surveillance" strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute. The use of active surveillance increased from 14.5 percent to 42.1 percent of men with low-risk prostate cancer between 2010 and 2015, said the researchers, led by Brandon Mahal, MD, from the department of radiation oncology at Dana-Farber/Brigham and Women's Cancer Center who led the study published by JAMA. During that same period, the percentage of men undergoing radical prostatectomy (removal of the prostate gland) declined from 47.4 percent to 31.3 percent. The use of radiotherapy for low-risk disease dropped from 38.0 percent [...]

2019-02-12T11:42:12+00:00February 12th, 2019|

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2019-01-15T11:04:18+00:00January 15th, 2019|

Study finds needle biopsy procedure may miss higher-risk cancer

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered. The research, which is published in the January edition of Mayo Clinic Proceedings, found for the first time that genetic alterations associated with intermediate- and high-risk prostate cancer also may be present in some cases of low-risk prostate cancers. The study found the needle biopsy procedure may miss higher-risk cancer that increases the risk of disease progression. Researchers say that men diagnosed with low-risk cancer may benefit from additional testing for these chromosomal alterations. "We have discovered new molecular markers that can help guide men in their decisions about the course of their prostate cancer care," says George Vasmatzis, [...]

2019-01-08T11:03:52+00:00January 8th, 2019|

Excess body weight contributes to aggressive prostate cancer risk

Researchers look at differences between states with the highest and lowest proportions of cancers attributable to excess body weight A new study looking at the share of cancers related to obesity finds an at least 1.5-fold difference between states with the highest and lowest proportions. The proportion of cancer cases that could be attributable to excess body weight ranged from a high of 8.3% in the District of Columbia to a low of 5.9% in Hawaii, reflecting variations in obesity rates in the states. The study appears in JAMA Oncology. Excess body weight is an established cause of cancer, currently known to be linked to 13 cancers. While differences in excess body weight among states in the United States are well-known, there is little [...]

2019-01-02T10:35:55+00:00January 2nd, 2019|

Study discovers link between inflammatory bowel disease and prostate cancer

. Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine. This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer. About 1 million men have inflammatory bowel disease in the U.S. Inflammatory bowel disease is a common chronic condition that includes Crohn's disease and ulcerative colitis. "These patients may need to be screened more carefully than a man without inflammatory bowel disease," said lead study author Dr. Shilajit Kundu. "If a man with inflammatory bowel disease has an elevated PSA, it may be an [...]

2018-12-11T08:37:12+00:00December 11th, 2018|

New study looks to determine type of prostate cancer — dangerous or manageable

Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could be hindered as a result of treating all prostate cancers in the same way. A team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy. Professor Norman Maitland, from the University of York's Department of Biology, said: "Unnecessary prostate treatment has both physical consequences for patients and their families, [...]

2018-11-20T07:52:53+00:00November 20th, 2018|

Commonality found between lung and prostate cancers

UCLA researchers have discovered a common process in the development of late-stage, small cell cancers of the prostate and lung. These shared molecular mechanisms could lead to the development of drugs to treat not just prostate and lung cancers, but small cell cancers of almost any organ. The key finding: Prostate and lung cells have very different patterns of gene expression when they're healthy, but almost identical patterns when they transform into small cell cancers. The research suggests that different types of small cell tumors evolve similarly, even when they come from different organs. The study, led by Dr. Owen Witte, founding director of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and professor of microbiology, immunology and [...]

2018-10-09T09:22:01+00:00October 9th, 2018|

New study reviews PSA screening results following prostate cancer treatment

A study assessed whether monitoring prostate cancer patients following treatment with a PSA test every three months versus once a year would provide a long-term survival benefit. Prostate cancer patients who were monitored more frequently after treatment did not live significantly longer than patients who were monitored once a year, according to study findings led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. At the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented findings on Friday, June 1, from an analysis of data from nearly 10,500 prostate cancer patients in the United States from 2005 to 2010. The study's primary goal was to determine if more frequent monitoring with the prostate-specific antigen test after treatment improved patients' [...]

2018-06-05T11:03:37+00:00June 5th, 2018|

New biopsy technology may identify better course of treatment for prostate cancer

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide, according to 2012 numbers. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments. Researchers in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto have developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered. "Screening for drug resistance is key to improving treatment approaches for many cancers," said Shana Kelley, scientist and professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. "It's important for patients not to be on a [...]

2018-04-24T10:27:34+00:00April 24th, 2018|

Wives of many prostate cancer sufferers challenged by the disease

Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband’s illness, with nearly half reporting that their own health suffered. In addition a focus subgroup has revealed that many feel isolated and fearful, and worry about the role change in their lives as their husband’s cancer advances. This study, developed with the wives of men with metastatic prostate cancer who were being treated with hormone therapy, is amongst the first carried out on how prostate cancer affects the partners of sufferers. It was presented yesterday at the EAU conference in Copenhagen. Prostate cancer is the most common male cancer. Prostate cancer which metastisises to other parts of the body is often difficult or impossible to cure, and [...]

2018-03-27T16:53:05+00:00March 27th, 2018|